What is HC Wainwright's Estimate for TERN Q3 Earnings?

Key Points

• HC Wainwright predicts Terns Pharmaceuticals will report a Q3 2025 earnings per share of (-$0.35) and has set a price target of $7.44 with a "Neutral" rating.
• BMO Capital Markets lowered its price target on Terns from $26.00 to $15.00, while three analysts maintain a "Buy" rating and two have a "Hold" rating.
• Terns Pharmaceuticals stock saw a 2.3% increase recently, currently trading at $7.22, with a market cap of $631.82 million.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Terns Pharmaceuticals in a research report issued on Thursday, September 4th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.35) for the quarter. HC Wainwright currently has a "Neutral" rating and a $7.44 price target on the stock. The consensus estimate for Terns Pharmaceuticals' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Terns Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.47) EPS.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ TERN traded down $0.21 during mid-day trading on Monday, hitting $7.23. The company had a trading volume of 1,872,404 shares, compared to its average volume of 1,106,887. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $10.70. The stock has a market cap of $632.70 million, a price-to-earnings ratio of -6.95 and a beta of -0.04. The firm's 50 day simple moving average is $6.25 and its two-hundred day simple moving average is $4.26.

Hedge Funds Weigh In On Terns Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Thrive Wealth Management LLC acquired a new position in shares of Terns Pharmaceuticals in the 1st quarter worth $29,000. Engineers Gate Manager LP purchased a new position in Terns Pharmaceuticals in the 2nd quarter worth about $41,000. Canada Pension Plan Investment Board purchased a new position in Terns Pharmaceuticals in the 2nd quarter worth about $46,000. LeConte Wealth Management LLC purchased a new position in Terns Pharmaceuticals in the 2nd quarter worth about $47,000. Finally, Vontobel Holding Ltd. purchased a new position in Terns Pharmaceuticals in the 1st quarter worth about $39,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CFO Andrew Gengos bought 10,000 shares of the stock in a transaction that occurred on Friday, June 27th. The shares were purchased at an average cost of $3.93 per share, for a total transaction of $39,300.00. Following the transaction, the chief financial officer directly owned 25,000 shares in the company, valued at $98,250. The trade was a 66.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs bought 23,314 shares of the stock in a transaction that occurred on Wednesday, June 25th. The stock was acquired at an average price of $3.87 per share, for a total transaction of $90,225.18. Following the completion of the transaction, the chief executive officer owned 47,083 shares in the company, valued at $182,211.21. This trade represents a 98.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 38,314 shares of company stock worth $149,275. 1.50% of the stock is owned by insiders.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.